A clinical study of the selective MAO-A-inhibitor moclobemide (Ro 11-1163): a comparison of 2 different dosages with particular reference to platelet MAO-activity and urinary MHPG-excretion.
A new selective MAO-A-inhibitor (noclobemide) was used in a double-blind comparative study of 23 patients with severe unipolar or bipolar depressive disorder. Two different doses of medication were given for 4 weeks. Effectiveness was measured by improvements in the Hamilton Rating Scale for Depression, a self-rating scale and clinical global impression. Platelet MAO-activity and urinary MHPG-excretion was also determined. Moclobemide proved to be a well-tolerated and effective antidepressant, with both groups showing improvement. Platelet MAO-activity was not markedly influenced by moclobemide, possibly because it selectively inhibits MAO-A. Urinary MHPG did not change significantly with treatment.
Lensch
K
K
Fuchs
G
G
Böning
J
J
Milech
U
U
D000328:Adult; D000368:Aged; D001549:Benzamides / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000201:enzymology; D001792:Blood Platelets / Q000201:enzymology; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy* / Q000201:enzymology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006018:Glycols / Q000652:urine*; D006801:Humans; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000652:urine*; D008875:Middle Aged; D020912:Moclobemide; D008995:Monoamine Oxidase / Q000097:blood*
D001549:Benzamides; D006018:Glycols; D008734:Methoxyhydroxyphenylglycol; D008995:Monoamine Oxidase; D020912:Moclobemide